{"url_path":"/sec/revb/8-k/2026-06-24/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-281200-index.html","accession_number":"0001193125-26-281200","cik":"0001810560","ticker":"REVB","issuer_name":"REVELATION BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-281200-index.html","primary_entity_key":"0001810560","primary_entity_name":"REVELATION BIOSCIENCES, INC."},"word_count":123,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n \n\n(d) Exhibits.\n\n \n\n \n\n \n\n \n\nExhibit No.\n\n \n\nDescription\n\n3.1\n\n \n\n[Third Amended and Restated Bylaws](revb-ex3_1.htm)\n\n10.1\n\n \n\n[Amended and Restated Executive Employment Agreement between Revelation Biosciences, Inc. and James Rolke, effective June 24, 2026](revb-ex10_1.htm)\n\n10.2\n\n \n\n[Amended and Restated Executive Employment Agreement between Revelation Biosciences, Inc. and Chester S. Zygmont, III, effective June 24, 2026](revb-ex10_2.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded with the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nREVELATION BIOSCIENCES, INC.\n\n \n\n \n\n \n\nDate: June 24, 2026\n\nBy:\n\n/s/ Chester S. Zygmont, III\n\n \n\n \n\nChester S. Zygmont, III\nChief Financial Officer\n(principal financial and accounting officer)"}